Ditchcarbon
  • Contact
  1. Organizations
  2. Camurus
Public Profile
Pharmaceutical Preparation Manufacturing
SE
updated 18 days ago

Camurus

Company website

Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.

DitchCarbon Score

How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

46

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Camurus's score of 46 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.

66%

Let us know if this data was useful to you

Camurus's reported carbon emissions

In 2023, Camurus reported total carbon emissions of approximately 5,618,000 kg CO2e globally, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions accounted for about 1,589,000 kg CO2e, while Scope 2 emissions totalled approximately 1,748,000 kg CO2e. Scope 3 emissions were notably high at around 3,856,000 kg CO2e, primarily driven by purchased goods and services, downstream transportation, and distribution activities. In Sweden, Camurus's emissions for 2023 were approximately 385,600 kg CO2e in Scope 3, with Scope 1 emissions at about 158,900 kg CO2e and Scope 2 emissions at approximately 11,680 kg CO2e (location-based). This reflects a commitment to transparency in their emissions reporting. Camurus has set ambitious climate commitments, aiming for a 35% reduction in greenhouse gas emissions by 2025 and a 55% reduction by 2030, using 2019 as the base year. Furthermore, the company has pledged to achieve carbon neutrality by 2040, demonstrating a long-term commitment to sustainability and climate action. These targets encompass all scopes of emissions, indicating a comprehensive approach to reducing their carbon footprint. Overall, Camurus's emissions data and climate commitments reflect a proactive stance in addressing climate change, aligning with industry standards and expectations for corporate responsibility.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
162,400
0,000,000
Scope 2
8,990
00,000
Scope 3
60,300
0,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Camurus's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Camurus is in SE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Camurus is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Abeona Therapeutics Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated about 16 hours ago

Td Medtekhnologii, Ooo

RU
•
Food products nec
Updated about 1 month ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251009.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy